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Background: Influenza virus infection is an important cause of under-five mortality. Maternal vaccination
protects children younger than 3 months of age from influenza infection. However, it is unknown to what
extent paediatric influenza-related mortality may be prevented by a maternal vaccine since global age-strati-
fied mortality data are lacking.
Methods: We invited clinicians and researchers to share clinical and demographic characteristics from chil-
dren younger than 5 years who died with laboratory-confirmed influenza infection between January 1, 1995
and March 31, 2020. We evaluated the potential impact of maternal vaccination by estimating the number of
children younger than 3 months with in-hospital influenza-related death using published global mortality
estimates.
Findings: We included 314 children from 31 countries. Comorbidities were present in 166 (53%) children and
41 (13%) children were born prematurely. Median age at death was 8¢6 (IQR 4¢516¢6), 11¢5 (IQR 4¢324¢0),
and 15¢5 (IQR 7¢427¢0) months for children from low- and lower-middle-income countries (LMICs), upper-
middle-income countries (UMICs), and high-income countries (HICs), respectively. The proportion of chil-
dren younger than 3 months at time of death was 17% in LMICs, 12% in UMICs, and 7% in HICs. We estimated
that 3339 annual influenza-related in-hospital deaths occur in the first 3 months of life globally.
Interpretation: In our study, less than 20% of children is younger than 3 months at time of influenza-related
death. Although maternal influenza vaccination may impact maternal and infant influenza disease burden,
additional immunisation strategies are needed to prevent global influenza-related childhood mortality. The
missing data, global coverage, and data quality in this study should be taken into consideration for further
interpretation of the results.
Funding: Bill & Melinda Gates Foundation.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)).
Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
Influenza virus is an important cause of mortality due to acute
lower respiratory infection (ALRI) in young children. In 2018, influ-
enza was associated with an estimated 15,300 (uncertainty range
[UR] 580043,800) in-hospital deaths in children younger than 5
years of age globally [1]. More than one third of in-hospital deaths
occurred in children younger than 6 months and the majority (82%)occurred in low-income (LICs) and lower-middle-income countries
(LMICs) [1]. Children younger than 6 months of age have higher rates
of influenza-associated hospitalisation and influenza-related mortal-
ity when compared to older children in high-income countries (HICs)
[2,3].
Paediatric influenza vaccines are licensed for children aged 6
months and older [4]. This leaves a gap in protection during the first
6 months of life. Maternal vaccination has the potential to protect
infants early in life through transplacental transfer of maternal anti-
bodies against influenza virus. The World Health Organization
(WHO) announced in 2012 that pregnant women should have the
Research in Context
Evidence before this study
Influenza infection was associated with an estimated 15,300
(uncertainty range [UR] 580043,800) in-hospital acute lower
respiratory infection (ALRI) deaths in children younger than 5
years in 2018, of which 36% occurred in infants under 6 months.
The potential impact of maternal vaccination on paediatric
mortality is unclear as age-stratified data under 6 months at
time of death are lacking and maternally-derived influenza
antibodies provide protection up to the first 3 months of life.
We searched for articles published in English from January 1,
2014 to February 2, 2020 using PubMed and search terms con-
cerning influenza infection and childhood mortality. Publica-
tions originated from high-income countries (HICs) only and
there were no multi-country case series.
Added value of this study
To our knowledge, this is the first global case series of children
who died with laboratory-confirmed influenza infection report-
ing age-stratified data in young children. We provide clinical
and demographic characteristics of 314 paediatric in-hospital
deaths with laboratory-confirmed influenza infection from 31
countries. In our study, 91 children (29%) were from LMICs.
Less than 20% of children dying in-hospital with influenza were
younger than 3 months at time of death and children from
LMICs were younger (8¢6 months) than children from HICs
(15¢5 months) at time of death.
Implications of all the available evidence
Our data show that maternal vaccination may prevent a higher
proportion of influenza-related in-hospital deaths in children
in LMICs than in other World Bank income regions. However,
even in LMICs, more than 80% of children are 3 months or older
at time of influenza-related in-hospital death. This implies that
a maternal vaccine could maximally prevent a small proportion
of global paediatric influenza-related in-hospital mortality and
other strategies are expected to have greater impact. By apply-
ing the proportions of children younger than 3 months at time
of death to global mortality estimates, we calculated that
maternal vaccination can potentially prevent up to 3339 (UR
12879886) influenza-related in-hospital deaths in children
younger than 5 years annually. The missing data, global cover-
age, and data quality in this study should be taken into consid-
eration for further interpretation of the results.
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several countries have incorporated maternal influenza vaccination
into routine immunisation programs, although implementation has
been negligible in LMICs due to logistical challenges, vaccine accep-
tance, and costs [6]. In 2014, the Board of Gavi, the Vaccine Alliance,
advocated for more evidence of vaccine impact on infants’ health out-
come to support maternal influenza vaccination programmes in
countries eligible for their support [7]. The efficacy of maternal influ-
enza vaccination has been demonstrated in 4 randomised controlled
trials, reducing laboratory-confirmed influenza in infants by 3063%
in the first 6 months of life [811].
In the secondary analysis of a maternal influenza vaccine trial
duration of protection by maternal vaccination was shown to be lim-
ited to the first 3 months of life due to the decline of maternally-
derived antibodies [12]. However, it remains unknown to whatextent maternal influenza vaccination could prevent influenza-
related mortality in infants, as global granular data on age distribu-
tion under 6 months at time of death are lacking [13]. Studies exam-
ining vaccine efficacy against influenza-related mortality from
countries where maternal vaccination has been implemented
exclude children younger than 6 months of age or do not collect
maternal vaccination data [2,13,14]. Thus, the potential impact of
maternal influenza vaccination on paediatric influenza-related mor-
tality remains unknown.
To gain insight into the age distribution and clinical characteristics
of influenza-related mortality in young children worldwide, we initi-
ated the FLU Global Online Mortality Database (FLU GOLD) study.
Using retrospective data, we determined the characteristics and age
distribution of children younger than 5 years who died in-hospital
with laboratory-confirmed influenza infection worldwide. Applying
the proportions of children younger than 3 months at time of death
to global mortality estimates, we estimated the potential impact of
maternal influenza vaccination on in-hospital paediatric-related
death.2. Methods
2.1. Study design and patients
The FLU GOLD study was initiated in October 2017. We invited our
existing global respiratory syncytial virus (RSV) GOLD network [15],
consisting of individual investigators, research groups, and clinicians,
to share individual-level data of children aged 059 months who
had died with laboratory-confirmed influenza infection between Jan-
uary 1, 1995 and March 31, 2020. YNL, NIM, FSV, and LJB had full
access to all the data in the study. We excluded community deaths
due to limited available data (n = 8) and children with influenza-
related mortality after stem cell transplantation. Additionally, we
searched the literature using PubMed for “influenza” combined with
“death”, “deaths”, “died”, “mortality”, “fatality”, or “case fatality ratio
(CFR)” and “pediatric”, “pediatrics”, “child”, or “children” and invited
authors to share additional (unpublished) cases. Collaborators were
invited to share data between October 13, 2017, and March 31, 2020
through a link to a questionnaire (Supplementary Material) in
Research Online, an electronic data capture platform [16].2.2. Definitions
We collected demographic and clinical characteristics and com-
pared these between children from different income groups. Coun-
tries of origin were categorised as LMIC (LIC and LMIC combined),
upper-middle-income countries (UMIC), and HIC according to the
World Bank classifications for 2020 [17]. We compared age distribu-
tion at time of death for the 3 income groups and between the follow-
ing 3 patient populations: children with comorbidities, healthy term
children, and healthy preterm children (without comorbidities). A
comorbidity was defined as at least one underlying disease, such as
congenital heart disease, chronic lung disease or a genetic disorder.
Prematurity was defined as gestational age less than 37 weeks. If
data for comorbidities or prematurity were not reported, we assumed
that the children were healthy term. We calculated weight-for-age z-
scores as previously described [15]. We determined the proportion of
children who died within the influenza virus epidemic season by
comparing age at death and seasonality within the country of origin
as estimated by a recent systematic analysis on global patterns of
monthly influenza virus activity [18]. We compared the proportion of
in-hospital deaths under 6 months of age in our study to the propor-
tions from published studies used for the recent global influenza bur-
den study from the Respiratory Virus Global Epidemiology Network
[1].
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We calculated age at influenza infection by subtracting the num-
ber of days between onset of influenza-related symptoms and influ-
enza-related death from age at influenza-related death. We then
determined the proportion of children under 3 months of age at time
of influenza infection.
2.4. Community-acquired and hospital-acquired influenza-related
death
We differentiated between children with community-acquired
and hospital-acquired influenza infection. In case the setting whereFig. 1. Flowchart of included deaths.
RSV=respiratory syncytial virus. GOLD=global online database. LMIC=low-income an
income countries. *For 1 child the collaborator had indicated in the comments that the deathinfluenza had been acquired was not provided, and if there were no
strong indications of nosocomial infection based on timeframe and
clinical disease course, we assumed the infection had been commu-
nity-acquired. We assumed that deaths occurred within the hospital
if data on location of death were missing.
2.5. Potential impact of maternal influenza vaccination on influenza-
related in-hospital death
To evaluate the minimum expected impact of maternal vaccina-
tion on influenza-related deaths assuming 100% vaccine efficacy and
complete vaccination coverage, we multiplied the proportion of chil-
dren younger than 3 months at time of community-acquired in-d lower-middle-income countries. UMIC=upper-middle-income countries. HIC=high-
was not influenza-related.
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associated ALRI in-hospital deaths under 5 years of age for each
World Bank income group [1].2.6. Sensitivity analyses
We compared demographic and clinical characteristics between
different income groups, excluding cases with missing data for
comorbidities or prematurity. We performed subgroup analyses and
compared characteristics for children with hospital-acquired and
community-acquired influenza-related death. Furthermore, we dif-
ferentiated between seasonal and pandemic influenza-related deaths
by excluding children with influenza A(H1N1)pdm09 who died
within the timeframe of the WHO-declared pandemic (June 2009 -
August 2010) from the analyses. Lastly, we analysed to what extent
our results were sensitive to the contribution of a large number of
cases from Ecuador, United Kingdom, Kenya, Turkey and South Africa
(n = 145) by excluding these countries from our analyses.2.7. Ethical approval
Since de-identified secondary patient data were used in the FLU
GOLD study, parental informed consent was waived by the institu-
tional research board of the University Medical Centre Utrecht. Ethi-
cal approval was obtained for individual collaborating institutes
when required.2.8. Statistical analysis
We report descriptive statistics for all variables. Continuous varia-
bles are presented as median with interquartile ranges (IQR). Cate-
gorical variables are presented as frequencies and proportions. We
used the x2-test or the Fisher’s exact test to determine statistical sig-
nificance between groups for categorical parameters. We report con-
servative exact p values instead of asymptotic p values because of the
small sample size. The Mann-Whitney U test was used for all continu-
ous parameters. We applied the Bonferroni correction for multipleFig. 2. Countries of children with influenza-related in-hospital death included in the analysi
Number of included deaths are given for each country (in pink) from which collaboratortesting between World Bank income groups. All statistical analyses
were performed with SPSS (version 21¢0; IBM Corp, Armonk, NY).2.9. Role of the funding source
The funder had no role in study design, data collection, data analy-
sis, data interpretation, writing of the report, or the decision to sub-
mit the paper for publication. YNL, NIM, FSV, and LJB had full access
to all the data in the study and NIM had final responsibility for the
decision to submit for publication.3. Results
We obtained data from both published and unpublished cases and
included 314 influenza-related deaths from 6 WHO regions and 31
countries (9 LMICs [29%], 9 UMICs [29%], and 13 HICs [42%]) across
the world (Figs. 1 and 2, Supplemental Table 1). The majority of cases
were shared through the RSV GOLD network and additional cases
were identified through the literature search [19,20]. In total, 91
(29¢0%) children were from LMICs, 115 (36¢6%) were from UMICs and
108 (34¢4%) were from HICs.
3.1. Clinical and demographic characteristics
Comorbidities were present in at least 166 (52¢9%) children and
41 (13¢1%) children were born prematurely (Table 1). Paediatric influ-
enza vaccination had been administered to 11 (3¢5%) children. Out of
31 children for which data on maternal immunisation were available,
2 children (Chile, n = 1 and US, n = 1) had mothers who had been vac-
cinated against influenza during pregnancy. Age at death for these
children was 15 and 16 months, respectively. Type of diagnostic
influenza tests used and additional characteristics for children from
different income countries are included in Supplemental Tables 2
and 3, respectively. Co-pathogens were identified in respiratory sam-




Clinical and demographic characteristics of children younger than 5 years with influenza-related in-hospital death.
LMICs (n = 91) p value* UMICs (n = 115) p valuey HICs (n = 108) p valuez Total (n = 314)
Male sex 46 (50¢5%) 0¢58 53 (46¢1%) 0¢08 62/107 (57¢9%) 0¢32 161/313 (51¢4%)
Age at death (months) 8¢6 (4¢516¢6) 0¢12 11¢5 (4¢324¢0) 0¢06 15¢5 (7¢427¢0) <0¢001 12¢0 (5¢024¢0)
<3 months at death 15 (16¢5%) 0¢42 14 (12¢2%) 0¢27 8 (7¢4%) 0¢07 37 (11¢8%)
<6 months at death 30 (33¢0%) 0¢76 35 (30¢4%) 0¢07 21 (19¢4%) 0¢04 86 (27¢4%)
Year of death 2015 (20112018); n = 91 0¢32 2014 (20122017); n = 112 0¢004 2012 (20102016); n = 107 0¢001 2013 (20112017); n = 310
Age at infection (months) 7¢6 (2¢917¢4); n = 64 0¢07 11¢3 (3¢823¢9); n = 107 0¢08 15¢9 (6¢729¢7); n = 79 0¢001 11¢5 (4¢524¢0); n = 250
<3 months at infection 19 (20¢9%) 0¢86 22 (19¢1%) 0¢09 11 (10¢2%) 0¢05 52 (16¢6%)
Type of influenza
A H1N1 pre-pandemic 3/81 (3¢7%) 1¢00 5/108 (4¢6%) 0¢45 2/102 (2¢0%) 0¢66 10/291 (3¢4%)
A H1N1 pdm-09 14/81 (17¢3%) 0¢03 34/108 (31¢5%) 0¢09 44/102 (43¢1%) <0¢001 92/291 (31¢6%)
A H1N2 0/81 1¢00 1/108 (0¢9%) 1¢00 0/102 1/291 (0¢3%)
A H3N2 6/81 (7¢4%) 0¢17 16/108 (14¢8%) 0¢08 7/102 (6¢9%) 1¢00 29/291 (10¢0%)
B Yamagata 0/81 0/108 0/102 0/291
B Victoria 0/81 0/108 0¢49 1/102 (1¢0%) 1¢00 1/291 (0¢3%)
A unsubtyped 32/81 (39¢5%) 0¢02 25/108 (23¢1%) 1¢00 23/102 (22¢5%) 0¢02 80/291 (27¢5%)
B unsubtyped 26/81 (32¢1%) 0¢75 32/108 (29¢6%) 0¢65 27/102 (26¢5%) 0¢42 85/291 (29¢2%)
Other^ 2/81 (2¢5%) 0¢58 1/108 (0¢9%) 1¢00 0/102 0¢20 3/291 (1¢0%)
Comorbidityx 37 (40¢7%) 0¢001 73 (63¢5%) 0¢10 56 (51¢9%) 0¢12 166 (52¢9%)
Prematurityx 8 (8¢8%) 0¢28 16 (13¢9%) 0¢71 17 (15¢7%) 0¢20 41 (13¢1%)
Gestational age (weeks) 38¢0 (34¢039¢0); n = 11 0¢84 38¢0 (35¢039¢0); n = 38 0¢54 38¢0 (34¢340¢0); n = 52 0¢95 38¢0 (35¢039¢0); n = 101
Length of stay in hospital (days) 6¢5 (3¢012¢8); n = 84 0¢005 9¢0 (4¢019¢0); n = 109 0¢95 11¢5 (3¢025¢8); n = 88 0¢02 8¢0 (3¢018¢0); n = 281
Intensive care unit (ICU) admission 47/83 (56¢6%) 0¢10 75/109 (68¢8%) <0¢001 86/89 (96¢6%) <0¢001 208/281 (74¢0%)
Length ICU admission (days) 4¢5 (1¢812¢3); n = 38 0¢004 10¢5 (4¢024¢5); n = 52 0¢17 8¢0 (2¢022¢0); n = 83 0¢10 8¢0 (3¢019¢5); n = 173
ICU not available 13/83 (15¢7%) <0¢001 0/109 0/89 <0¢001 13/281 (4¢6%)
Respiratory support 40/82 (48¢8%) <0¢001 68/72 (94¢4%) 0¢17 88/89 (98¢9%) <0¢001 196/243 (80¢7%)
Mechanical ventilation 16/82 (19¢5%) <0¢001 48/72 (66¢7%) <0¢001 82/89 (92¢1%) <0¢001 146/243 (60¢1%)
Respiratory support not available 31/82 (37¢8%) <0¢001 0/72 0/89 <0¢001 31/243 (12¢8%)
Time between onset of symptoms
and hospital admission (days)
4¢0 (2¢07¢0); n = 64 <0¢001 2¢0 (0¢04¢0); n = 110 0¢96 2¢0 (1¢03¢0); n = 80 <0¢001 2¢0 (1¢04¢3); n = 254
Time between onset of symptoms
and death (days)
12¢0 (7¢019¢8); n = 64 0¢63 12¢0 (7¢024¢0); n = 107 0¢83 12¢0 (5¢027¢0); n = 79 0¢73 12¢0 (6¢022¢3); n = 250
Death during influenza season 64 (70¢3%) 0¢08 65/112 (58¢0%) 0¢57 60/96 (62¢5%) 0¢28 189/299 (63¢2%)
Data are n (%), n/N (%) or median (IQR); n. Statistical comparisons with x2 test using exact p values, Fisher’s exact test or Mann-Whitney U test with p values of less than 0¢0167 taken to be significant according to
the Bonferroni correction for multiple testing. LMIC=low-income and lower-middle-income countries. UMIC=upper-middle-income countries. HIC=high-income countries. *Low-income or lower-middle-income
country versus upper-middle-income country. yUpper-middle-income country versus high-income country. zLow-income or lower-middle-income country versus high-income country. ^These children were












Fig. 3. A) Age younger than 3 months or 3 months and older at time of influenza-related in-hospital death for children younger than 5 years from low- and lower-middle-income
countries (LMIC), upper-middle-income countries (UMIC), and high-income countries (HIC). B) Age distribution at time of influenza-related in-hospital death for children younger
than 5 years from low- and lower-middle-income countries (LMIC), upper-middle-income countries (UMIC), and high-income countries (HIC).
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Globally, more than 80% of paediatric influenza-related deaths
occurred after the first 3 months of life. The proportion of children
younger than 3 months at time of death was 16¢5% in LMICs, 12¢2% in
UMICs and 7¢4% in HICs (Fig. 3A). The proportions of children younger
than 6 months at time of death were 33¢0% in LMICs, 30¢4% in UMICs,
and 19¢4% in HICs. Median age at death was 8¢6, 11¢5 and 15¢5
months for children from LMICs, UMICs, and HICs, respectively
(Fig. 3B). Children from LMICs were younger at time of death than
children from HICs (p<0¢001). The age distribution for pretermchildren without comorbidities, term children with comorbidities,
and healthy term children is shown in Supplemental Figure 1.
3.3. Hospital-acquired influenza-related death
We separately described variables for 38 (12¢1%) children with
hospital-acquired influenza-related death and compared these to
children with community-acquired influenza-related death (Supple-
mental Table 5). Age at death, and time between onset of influenza-
related symptoms and death did not differ significantly between
both groups (p = 0¢09 and p = 0¢14, respectively). More children with
Table 2
Global paediatric influenza-associated in-hospital deaths in children younger than 5 years.
Estimated number of global annual influenza-related
ALRI deaths in children younger than 5 years[1]
Proportion of children younger
than 3 months (FLU GOLD registry)
Potentially prevented influenza-related
ALRI in-hospital death*
LMIC 17,000 (690045,100) 17¢2% 2924 (11877757)
UMIC 3200 (80014,400) 11¢6% 371 (931670)
HIC 600 (1006200) 7¢4% 44 (7459)
Overall 3339 (12879886)**
Data are provided in numbers and uncertainty ranges. ALRI=acute lower respiratory infection. LMIC=low-income and lower-middle-income countries.
UMIC=upper-middle-income countries. HIC=high-income countries.
*Percentage of children younger than 3 months with in-hospital, community-acquired influenza-related death from the FLU GOLD registry (n = 276,
Supplemental Table 6) was multiplied with the number of global estimated deaths as reported by Wang et al. [1] for each income group. By analyzing
the income groups separately, we accounted for the fact that the proportion of children from LMICs in the FLU GOLD registry is not representative for
the total global burden in this population.
**Overall number was calculated by summing up the number of potentially prevented influenza-related ALRI in-hospital deaths for each World Bank
income level group.
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compared to children with community-acquired influenza-related
death (36¢8% versus 9¢8%, p<0¢001). Although timing of intensive
care unit (ICU) admission in relation to influenza infection was
unknown, all children with hospital-acquired influenza-related death
had been admitted to the ICU. This differed from children with com-
munity-acquired influenza-related death, of which 70¢1% had been
admitted to the ICU (p<0¢001).
3.4. Potential impact of maternal vaccination on influenza-related in-
hospital death
Based on published global mortality estimates, we calculated that
3339 (UR 12879886) influenza-related in-hospital deaths occurred
annually in children younger than 3 months (Table 2).
3.5. Sensitivity analyses
When excluding children with hospital-acquired influenza-
related mortality (n = 38) from the analyses, differences in character-
istics between income groups remained unchanged, except for the
length of hospital and ICU stay, and the presence of comorbidities
between children from LMICs and UMICs (Supplemental Table 6).
We also analyzed our data after excluding children with missing
data for prematurity and comorbidities (n = 150). Results for age dis-
tribution remained unchanged, including a higher age at death for
children from HICs (14¢5 months [IQR 6¢128¢6]) than from UMICs
(12¢0 months [IQR 4¢028¢9]) and LMICs (9¢2 months [IQR
4¢023¢2]) (Supplemental Table 7), although the difference in age at
death for children from HICs compared to children from LMICs was
no longer significant. Furthermore, when excluding 26 children with
influenza A(H1N1)pdm09 virus infection who died within the time-
frame of the WHO-declared pandemic (June 2009 - August 2010),
conclusions did not change (Supplemental Table 8).
Lastly, we analysed our data after excluding children from Ecua-
dor, Kenya, United Kingdom, Turkey, and South Africa (n = 145), as
these accounted for almost half of all influenza-related deaths
(Fig. 2). As these were mainly UMIC deaths (n = 89), median age at
death for children from UMICs increased to 23¢5 months (IQR
9¢939¢0) and there were more children with comorbidities from
HICs (62¢8%) as compared to children from LMICs (30¢8%, p<0¢001)
(Supplemental Table 9).
4. Discussion
To our knowledge, the FLU GOLD study is the first global case
series reporting on influenza-related deaths in children under 5 years
of age. We collected demographic and clinical characteristics ofchildren who died with influenza virus infection in the hospital from
31 countries. We showed that more than 80% of children were 3
months or older at time of influenza-related death. This finding
implies that maternal vaccine alone would be insufficient to prevent
the majority of global paediatric influenza-related in-hospital mortal-
ity, given that the duration of protection is limited to the first 3
months of life [12]. We estimated that a total of 3339 influenza-
related in-hospital deaths in infants younger than 3 months could
have been potentially prevented by maternal vaccination, which is
21¢8% of the global influenza-related paediatric mortality burden [1].
Maternal vaccination may have a higher impact on influenza-related
paediatric in-hospital deaths in LMICs as we observed a trend
towards a higher proportion of children dying below the age of 3
months in LMICs compared to other income regions. Since we
reported conservative p values, this difference may be significant in
larger sample sizes.
Our findings are in line with a systematic review of the global bur-
den of influenza-associated in-hospital deaths in children under 5
years in which 36% of deaths occurred in children younger than 6
months. Moreover, the highest number of deaths was estimated to
occur in children aged 1259 months, comparable to our results [1].
We found that at least 53% of children had comorbidities which is
similar to results from other studies [21,22] In contrast, in a study
from the United Kingdom that evaluated all influenza-related paedi-
atric ICU admissions between 2003 and 2015, nearly four fifths of
children had high-risk conditions [23]. The Advisory Committee on
Immunization Practices (ACIP) from the United States Centers for Dis-
ease Control and Prevention (CDC) recommends vaccination for chil-
dren aged 6 months and older and recognises that children with the
following underlying conditions are at increased risk of developing
medical complications attributable to severe influenza infection:
chronic pulmonary disease, hemodynamically significant cardiovas-
cular disease, immunosuppression, renal, hepatic, neurological,
hematologic, or metabolic disorders [4]. In our registry, congenital
heart disease and neurological disease were the most reported
comorbidities. Prematurity was present in 13% of children, but data
were missing for 48% of all children included in the study. Comorbid-
ities were less often reported in children from LMICs than from
UMICs. This may have been caused by lack of available clinical data or
limited access to adequate healthcare resources resulting in a higher
number of influenza-related deaths in previously healthy children.
Children from LMICs were younger at time of influenza-related
death, had a longer time interval between onset of symptoms and
hospital admission and were less often admitted to the ICU as com-
pared to children from UMICs and HICs. These findings might be due
to poor access to healthcare and limited availability of ICU beds
rather than underlying susceptibility of these children to influenza.
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to pre-existing susceptibility from underlying conditions.
Paediatric deaths associated with influenza A(H1N1)pdm09 virus
were proportionately higher in HICs than LMICs. This is likely caused
by publication bias since there were more studies on influenza A
(H1N1)pdm09 virus available from HICs than from LMICs. Further-
more, information on influenza subtype in LMICs was not always
available, which also may have contributed to this difference.
Beyond the scope of this paper, we compared our data to 358 pre-
viously reported cases from the RSV GOLD I study of children under 5
years of age with RSV-related in-hospital mortality [15], as RSV is
currently the most common viral pathogen causing ALRI in young
children. Children with influenza-related death were substantially
older than children with RSV-related death (Supplemental Table 10,
Supplemental Figure 2). This difference was also demonstrated in
other studies [24]. In a prospective Dutch birth cohort of 4072 prema-
ture infants [25], 181 infants were hospitalised with RSV infection
and 2 with influenza infection in the first year of life (data not
shown), indicating that severe ALRI due to influenza is less prevalent
than RSV in younger children. Reasons for this age difference are
likely multifactorial. In contrast to influenza, RSV predominantly
affects the airways and causes greater epithelium damage [26], lead-
ing to significant airway obstruction and fatality in infants who have
smaller airways than older children. Additionally, coinfections, which
could cause mortality also in older children, may occur less often in
children with RSV infection compared to children with influenza
infection [27].
For the first time, we report global age-stratified data for children
dying with influenza. This enabled us to assess the potential impact
of maternal vaccination on paediatric influenza-related mortality.
Furthermore, we verified each case through direct communication
with the local collaborators.
There are also limitations to this study. First, our results reflect
only a small proportion of paediatric influenza-related mortality
occurring worldwide, since limited data are available due to lack of
diagnostic testing, in particular from children who died outside of
the hospital. Our database included only 18 (5¢7%) children from LICs,
and this proportion should be much higher based on global mortality
burden estimates. Since children dying in the community may be
younger and are mainly from LMICs, our results are an underestima-
tion of the potential impact of maternal vaccination on paediatric
influenza-related mortality in LMICs. Furthermore, since we only
included individual-level patient data, it was not possible to use
larger published case series from the US for which only aggregated
data could be provided [3,20,2831]. The percentage of children
younger than 6 months within the under-five age group in these case
series ranged between 19% and 35%, which is slightly higher than we
report for HICs (19%). Second, we were unable to assess the potential
impact of maternal vaccination on stillbirths associated with in utero
influenza exposure. Furthermore, we were unable to assess the indi-
rect impact of maternal vaccination on paediatric mortality due to
bacterial pneumonia following influenza infection, all-cause ALRI,
deaths prevented due to herd immunity including young siblings, or
impact on postpartum maternal death and subsequent effects on the
health of the child. This limitation resulted in an underestimation of
the potential impact of maternal influenza vaccination on paediatric
mortality. Third, we did not account for maternal vaccination cover-
age, vaccine efficacy and potential programmatic limitations. Data on
maternal immunization during pregnancy was available for only 31
patients. For this reason we may show an overestimation of vaccine
impact. Fourth, our literature search terms were more limited than
those used for the global influenza burden study [1] resulting in
missed published deaths (91 deaths from 18 studies). From the
missed published deaths, age distribution data were available for 15
children, of which 3 (20%) were younger than 6 months at the time of
influenza-related death, which is similar to what we observed (27%).We therefore expect that this limitation does not have a major impact
on our study. Data were unavailable on the proportion of children
younger than 3 months in the missed deaths. Fifth, we have based
our estimations on the global influenza estimates from the global
burden study, which has its own limitations such as heterogeneity of
studies, several forms of bias and scarcity of data, which could have
caused both overestimations as underestimations of paediatric influ-
enza-related death burden according to the authors and therefore
could lead to over- or underestimation of vaccine impact on mortality
[1]. Moreover, data from LMICs were limited in this study which
likely leads to an underestimation of mortality burden. Sixth, some
authors did not respond to our invitation to collaborate, which could
have led to non-response bias. Seventh, data on location of death
were not always available. We assumed that these deaths occurred
within the hospital due to the limited number of studies and lack of
available influenza testing within the community. Furthermore, the
majority of children with missing data for location of death were
from HICs. It is unlikely that these children would not have been
admitted to hospital. Finally, data for prematurity and comorbidities
were often missing, in particular from LMICs, which could have
caused an underestimation of the number of children with prematu-
rity and comorbidity. However, when we excluded children with
missing data in the sensitivity analyses, the main results from this
study remained unchanged.
There are important factors to support maternal influenza vacci-
nation: it has proved to be safe [11] and effective in preventing influ-
enza-associated ALRI in both infants and pregnant women, the latter
forming a substantial risk group for influenza-associated hospitalisa-
tion [32] and death [33]. Furthermore, maternal influenza vaccination
decreased all-cause ALRI hospitalisations in infants during the first 3
months of life [34]. A study on maternal influenza vaccination among
HIV-infected and HIV-uninfected pregnant women in South Africa
showed that antenatal influenza vaccination campaigns in South
Africa would be cost-effective [35]. However, we showed that the
impact on paediatric influenza-related death may be limited since
more than 80% of global paediatric influenza-related in-hospital
deaths occurred after the first 3 months of life, which is beyond the
timeframe in which maternally-derived anti-influenza antibodies are
expected to have protective effect. Although maternal influenza vac-
cination may have more impact in LMICs where children with influ-
enza infection die at a younger age, additional immunisation
strategies and more high-quality patient data from LMICs are
required to prevent global paediatric influenza-related death. Studies
to develop a safe and effective influenza vaccine for children younger
than 6 months could be considered. In the context of SDG 3¢1 and
3¢2, maternal vaccination should continue to be emphasized and
additional strategies are needed to target influenza-related under-
five mortality. The missing data, global coverage, and data quality in
this study should be taken into consideration for further interpreta-
tion of the results.
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